Miravant's SnET2 Requires Additional Clinical Trial For Macular Degeneration
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.
You may also be interested in...
Miravant Plans Photrex Confirmatory Macular Degeneration Trial
The trial, to be conducted under a special protocol assessment with FDA, will be one year with another year for confirmatory results. Agency's September 2004 "approvable" letter for the photodynamic therapy requested an additional study. Miravant is also planning combination studies with other age-related macular degeneration agents.
Miravant Plans Photrex Confirmatory Macular Degeneration Trial
The trial, to be conducted under a special protocol assessment with FDA, will be one year with another year for confirmatory results. Agency's September 2004 "approvable" letter for the photodynamic therapy requested an additional study. Miravant is also planning combination studies with other age-related macular degeneration agents.
Concomitant Use Of Macugen With Visudyne Appears Safe, Cmte. Says
Concomitant use of Pfizer/Eyetech's Macugen (pegatanib) with Novartis/QLT's Visudyne (verteporfin) does not pose safety concerns, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded Aug. 27.